Immupharma PLC Clinical Development Collaboration with Incanthera (7735L)
December 31 2018 - 2:00AM
UK Regulatory
TIDMIMM
RNS Number : 7735L
Immupharma PLC
31 December 2018
31 December 2018
ImmuPharma PLC
("ImmuPharma" or the "Company")
UPDATE ON NUCANT CANCER PROGRAMME
Clinical Development Collaboration with Incanthera
ImmuPharma PLC (LSE: IMM), the specialist drug discovery and
development company provides an update on its clinical development
collaboration agreement for its Nucant cancer programme, with
Incanthera Limited ("Incanthera"), a specialist oncology
development company.
As announced on 7 December 2018, ImmuPharma alongside Incanthera
are making good progress in finalising the 'Definitive Licence
Agreement'. It has been agreed between both companies to extend the
exclusivity period, which was initially granted to 31 December
2018, to 31 March 2019, in order to finalise the remaining parts of
the agreement.
It is now envisaged that the 'Definitive Licence Agreement' will
be finalised in the first quarter of 2019 and as such, a further
update on this collaboration will be announced in due course.
Commenting, Dimitri Dimitriou, ImmuPharma's Chief Executive
Officer, said:
"We are working diligently with Incanthera's management team to
finalise the last remaining parts to the 'Definitive Licence
Agreement' and look forward to updating the market and shareholders
in Q1 2019."
This announcement contains inside information for the purposes
of Article 7 of Regulation (EU) 596/2014. ("MAR")
For further information please contact:
ImmuPharma plc (www.immupharma.com) + 44 (0) 207 152 4080
Dimitri Dimitriou, Chief Executive Officer
Lisa Baderoon, Head of Investor Relations + 44 (0) 7721 413496
SPARK Advisory Partners Limited (NOMAD)
Neil Baldwin +44 (0) 203 368 8974
Vassil Kirtchev
Stanford Capital Partners (Joint Broker)
Patrick Claridge, John Howes +44 (0) 203 815 8880
SI Capital (Joint Broker)
Nick Emerson +44 (0) 1483 413500
About Incanthera Limited
Incanthera Limited was formed in 2010 as a spin-out from
the Institute of Cancer Therapeutics at Bradford University
and is targeting the treatment of cancer through a portfolio
of unique technologies. Having successfully commercialised
its lead product in 2017, it is actively acquiring technologies
to further enhance its portfolio of cancer therapeutics.
For more information, please visit: www.incanthera.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCLFFELFTLAFIT
(END) Dow Jones Newswires
December 31, 2018 02:00 ET (07:00 GMT)
Immupharma (LSE:IMM)
Historical Stock Chart
From Jun 2024 to Jul 2024
Immupharma (LSE:IMM)
Historical Stock Chart
From Jul 2023 to Jul 2024